These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3475207)

  • 41. The influence of ofloxacin and enoxacin on the metabolic pathways of theophylline in healthy volunteers. A pilot study.
    Wijnands WJ; Janssen TJ; Guelen PJ; Vree TB; De Witte TM
    Pharm Weekbl Sci; 1988 Dec; 10(6):272-6. PubMed ID: 3211700
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of single doses of rufloxacin on the disposition of theophylline and caffeine after single administration.
    Cesana M; Broccali G; Imbimbo BP; Crema A
    Int J Clin Pharmacol Ther Toxicol; 1991 Apr; 29(4):133-8. PubMed ID: 2071262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [In vitro and in vivo activities of norfloxacin, ofloxacin and ciprofloxacin against various mycobacteria].
    Saito H; Sato K; Tomioka H; Watanabe T
    Kekkaku; 1987 May; 62(5):287-94. PubMed ID: 3114537
    [No Abstract]   [Full Text] [Related]  

  • 44. Inhibition of the oxidative metabolism of theophylline in isolated rat hepatocytes by the quinolone antibiotic enoxacin and its metabolite oxoenoxacin, but not by ofloxacin.
    Mulder GJ; Nagelkerke JF; Tijdens RB; Wijnands WJ; Van der Mark EJ
    Biochem Pharmacol; 1988 Jul; 37(13):2565-8. PubMed ID: 3164618
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ofloxacin: antibacterial activity, induction of resistance and killing curves.
    Husson MO; Izard D; Bryskier A; Leclerc H
    Chemioterapia; 1985 Aug; 4(4):278-83. PubMed ID: 3863716
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibacterial activity of ofloxacin and other 4-quinolone derivatives: in-vitro and in-vivo comparison.
    Chantot JF; Bryskier A
    J Antimicrob Chemother; 1985 Oct; 16(4):475-84. PubMed ID: 3864775
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Norfloxacin induced resistance to fluoroquinolones & structurally unrelated antimicrobial agents in coagulase negative staphylococci.
    Deshmukh SR; Nagoba BS; Wadher BJ; Tumane P
    Indian J Med Res; 1997 Nov; 106():461-4. PubMed ID: 9415741
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.
    Zeiler HJ
    Drugs Exp Clin Res; 1985; 11(5):335-8. PubMed ID: 2941261
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Comparison of in vitro growth-inhibitory activities of ofloxacin, ciprofloxacin and norfloxacin against various species of mycobacteria (comparison of organ concentrations and blood concentrations in mice)].
    Tsukamura M; Mizuno S; Toyama H
    Kekkaku; 1986 Sep; 61(9):453-9. PubMed ID: 3467134
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates.
    Periti P; Mazzei T; Nicoletti P
    Chemioterapia; 1987 Apr; 6(2):75-8. PubMed ID: 3474081
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative in vitro studies with 4-quinolone antimicrobials.
    Felmingham D; O'Hare MD; Robbins MJ; Wall RA; Williams AH; Cremer AW; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(5):317-29. PubMed ID: 2941259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decrease of caffeine elimination in man during co-administration of 4-quinolones.
    Stille W; Harder S; Mieke S; Beer C; Shah PM; Frech K; Staib AH
    J Antimicrob Chemother; 1987 Nov; 20(5):729-34. PubMed ID: 3480885
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interaction between quinolones and caffeine.
    Staib AH; Stille W; Dietlein G; Shah PM; Harder S; Mieke S; Beer C
    Drugs; 1987; 34 Suppl 1():170-4. PubMed ID: 3481318
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Comparative bactericidal kinetics of ciprofloxacin, ofloxacin and pefloxacin alone and in combination against strains of group D Streptococcus].
    Zuccarelli M; Simeon de Buochberg M; Maillols M; Armynot du Chatelet AM; Attisso MA
    Pathol Biol (Paris); 1988 May; 36(5):403-9. PubMed ID: 3136422
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fluoroquinolones reviewed.
    Drug Ther Bull; 1993 Aug; 31(18):69-72. PubMed ID: 8404463
    [No Abstract]   [Full Text] [Related]  

  • 56. Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid.
    Staib AH; Harder S; Fuhr U; Wack C
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):289-3. PubMed ID: 2737798
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of ofloxacin on the faecal flora.
    Midtvedt T
    Drugs; 1987; 34 Suppl 1():154-8. PubMed ID: 3481316
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The clinical pharmacokinetics of levofloxacin.
    Fish DN; Chow AT
    Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro activity of three fluoroquinolones against enterococci and Pseudomonas aeruginosa: modified categorization system for discrepant broth dilution and agar disk diffusion test results.
    Traub WH; Kohl KH; Spohr M
    Chemotherapy; 1988; 34(2):101-6. PubMed ID: 3134171
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics.
    Sörgel F; Mahr G; Granneman GR; Stephan U; Nickel P; Muth P
    Clin Pharmacokinet; 1992; 22 Suppl 1():65-74. PubMed ID: 1319873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.